Earnings summaries and quarterly performance for CG Oncology.
Executive leadership at CG Oncology.
Board of directors at CG Oncology.
Research analysts covering CG Oncology.
Recent press releases and 8-K filings for CGON.
CG Oncology Reports Q3 2025 Financial Results and Initiates BLA Submission
CGON
Earnings
Guidance Update
Product Launch
- CG Oncology reported a net loss of $43.8 million, or ($0.57) per share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company held $680.3 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the first half of 2028.
- The company initiated a rolling Biologics License Application (BLA) submission for cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC, with complete submission expected in 2026, and completed enrollment for the PIVOT-006 Phase 3 clinical trial.
Nov 14, 2025, 1:15 PM
Quarterly earnings call transcripts for CG Oncology.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track CG Oncology's earnings for you
Get instant analysis when filings drop